Bevacizumab Augments the Antitumor Efficacy of Infigratinib in Hepatocellular Carcinoma
出版年份 2020 全文链接
标题
Bevacizumab Augments the Antitumor Efficacy of Infigratinib in Hepatocellular Carcinoma
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 21, Issue 24, Pages 9405
出版商
MDPI AG
发表日期
2020-12-10
DOI
10.3390/ijms21249405
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
- (2018) Milind Javle et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Infigratinib mediates vascular normalization, impairs metastasis and improves chemotherapy in hepatocellular carcinoma
- (2018) Hung Huynh et al. HEPATOLOGY
- Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
- (2018) J. Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study
- (2017) Lucia Nogova et al. JOURNAL OF CLINICAL ONCOLOGY
- Fibroblast growth factor receptor 3 isoforms: Novel therapeutic targets for hepatocellular carcinoma?
- (2015) Jakob Paur et al. HEPATOLOGY
- Genomic characterization of a large panel of patient-derived hepatocellular carcinoma xenograft tumor models for preclinical development
- (2015) Qingyang Gu et al. Oncotarget
- EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2015) et al. JOURNAL OF HEPATOLOGY
- Fibroblast Growth Factor Receptor Inhibitors as a Cancer Treatment: From a Biologic Rationale to Medical Perspectives
- (2013) Maria Vittoria Dieci et al. Cancer Discovery
- FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor
- (2012) V. Guagnano et al. Cancer Discovery
- Beyond VEGF: Inhibition of the Fibroblast Growth Factor Pathway and Antiangiogenesis
- (2011) C. Lieu et al. CLINICAL CANCER RESEARCH
- Brivanib, a Dual FGF/VEGF Inhibitor, Is Active Both First and Second Line against Mouse Pancreatic Neuroendocrine Tumors Developing Adaptive/Evasive Resistance to VEGF Inhibition
- (2011) Elizabeth Allen et al. CLINICAL CANCER RESEARCH
- Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase
- (2011) Vito Guagnano et al. JOURNAL OF MEDICINAL CHEMISTRY
- Roles of Fibroblast Growth Factor Receptors in Carcinogenesis
- (2010) E. M. Haugsten et al. MOLECULAR CANCER RESEARCH
- The Significance of Fibroblast Growth Factor Receptor 2 Expression in Differentiation of Hepatocellular Carcinoma
- (2010) Norifumi Harimoto et al. ONCOLOGY
- Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
- (2009) John M.L. Ebos et al. CANCER CELL
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
- (2009) Marta Pàez-Ribes et al. CANCER CELL
- Resistance to EGF-R (erbB-1) and VEGF-R modulating agents
- (2009) Wolfram C.M. Dempke et al. EUROPEAN JOURNAL OF CANCER
- Hepatocellular Carcinoma Incidence, Mortality, and Survival Trends in the United States From 1975 to 2005
- (2009) Sean F. Altekruse et al. JOURNAL OF CLINICAL ONCOLOGY
- AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC)
- (2009) Hung Huynh et al. JOURNAL OF HEPATOLOGY
- The FGF family: biology, pathophysiology and therapy
- (2009) Andrew Beenken et al. NATURE REVIEWS DRUG DISCOVERY
- Lymphangiogenesis in Esophageal Adenocarcinomas--Lymphatic Vessel Density as Prognostic Marker in Esophageal Adenocarcinoma
- (2008) Reda S. Saad et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma
- (2008) Hung Huynh et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer
- (2008) Michael Höpfner et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma
- (2007) Andrew X. Zhu CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More